Related Experiment Video
Updated: May 7, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.4K
Topical and oral bexarotene.
1Medicine (Dermatology), University of Louisville, Louisville, Kentucky.
Dermatologic Therapy
|October 9, 2013
Summary
Bexarotene, a retinoid, treats cutaneous T cell lymphoma by affecting cell growth. While it has side effects like hyperlipidemia and dermatitis, careful management makes it a valuable treatment option.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Bexarotene is a retinoid targeting retinoid X receptors.
- It influences cellular growth and differentiation.
Purpose of the Study:
- To evaluate bexarotene as a treatment for cutaneous T cell lymphoma.
- To outline its efficacy and adverse effects.
Main Methods:
- Review of bexarotene's mechanism of action.
- Analysis of clinical data regarding its use in cutaneous T cell lymphoma.
Main Results:
- Bexarotene is approved for topical and systemic treatment of cutaneous T cell lymphoma.
- Adverse effects include hyperlipidemia, hypothyroidism, neutropenia (capsules), and irritant dermatitis (gel).
Conclusions:
- Bexarotene offers an additional therapeutic option for cutaneous T cell lymphoma.
- Aggressive management of side effects is crucial for successful treatment.
Related Concept Videos
01:27Acne Infection
99
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
99
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
01:15Non-Oral Extravascular Drug Absorption Routes
726
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
726
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
02:56Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K